Table 2.
Prostate cancer stem cells related inhibitors.
| Signaling Pathway | Name of Inhibitor | Target | Reference |
|---|---|---|---|
| Notch signaling pathway | PF-03084014 | γ-secretase | Cui D, et al., 2015 [128] |
| RO4929097 | γ-secretase | Du Z, et al., 2021 [166] | |
| DAPT(GSI-IX) | Notch-1 | Cui J, et al., 2018 [167] | |
| SOX8/RO04929097 | Notch-4 | Du Z, et al., 2022 [168] | |
| Hedgehog signaling pathway | GDC-0449 | SMO | Tong W, et al., 2018 [169] |
| GANT-61 | GLI | Tong W, et al., 2018 [169] | |
| vismodegib | SMO | Leao R, et al., 2017 [170] | |
| itraconazole | SMO | Leao R, et al., 2017 [170] | |
| sonidegib (LDE-225) | SMO | Burness CB, et al., 2015 [171] | |
| Wnt signaling pathway | LGK974 | Porcupine | Ma F, et al., 2016 [172] |
| DDK1 | LRP5 | Browne AJ, et al., 2016 [173] | |
| DKK3 | Frizzled/LRP5/6 complex | Bhattacharyya S, et al., 2019 [174] | |
| OMP-54F28 (Ipafricept) | Wnt family | Katoh M, et al., 2017 [175] | |
| OMP-18R5 (Vantictumab) | Frizzled1,2,5,7,8 | Katoh M, et al., 2017 [175] | |
| SFRP | Wnt ligands | Cruz-Hernandez CD, et al., 2020 [176] | |
| ETC-159 (ETC-1922159) | Porcupine | Katoh M, et al., 2017 [175] | |
| ICG001 | β-actin | Kelsey R, et al., 2017 [177] | |
| 3289-8625 | DVL | Schneider JA, et al., 2018 [178] | |
| STAT3 signaling pathway | Napabucasin (BBI608) | STAT3 gene transcription | Zhang Y, et al., 2016 [179] |
| Alantolactone (ALT) | STAT3(Tyr705) | Babaei G, et al., 2020 [180] | |
| EC-70124 | STAT3(Tyr705) | Civenni G, et al., 2016 [181] | |
| ruxolitinib | JAK | Han IH, et al., 2020 [182] | |
| PI3K/AKT signaling pathway | HIF1α | mTOR | Marhold M, et al., 2015 [183] |
| NVP-BEZ235 | PI3K and mTOR | Liu G, et al.,2020 [184] | |
| GSK2636771 | P110β/γ | Sarker D, et al., 2021 [185] | |
| LY3023414 AZD8186 |
P110α/β | Choudhury AD, et al., 2022 [186] Hancox U, et al., 2015 [187] |
|
| Apitolisib(GDC-0980), buparlisib |
pan-PI3K | Zhou Y, et al., 2015 [188] Armstrong AJ, et al., 2017 [189] |
|
| Ipatasertib MK2206 AZD5363 |
pan-AKT | Armstrong AJ, et al., 2017 [189] Sweeney C, et al., 2021 [190] |
|
| Everolimus Temsirolimus Ridaforolimus AZD2014, MLN0128 |
mTOR | Eule CJ, et al., 2023 [191] Kruczek K, et al., 2013 [192] Meulenbeld HJ, et al., 2013 [193] Li S, et al., 2021 [194] Graham L, et al., 2018 [195] |
|
| NF-κB signaling pathway | EC-70124 | IκB phosphorylation | Civenni G, et al., 2016 [181] |
| Eupatilin | NF-κB | Serttas R, et al., 2021 [196] | |
| JSH-23 | NF-κB | Chang KS, et al., 2019 [197] | |
| Hippo signaling pathway | STK3/4 | YAP1;TAZ | Schirmer AU, et al., 2022 [198] |
| verteporfin | YAP;YAP/TEAD complex | Li Q, et al., 2021 [199] | |
| Others | GSK2801 | BAZ2A | Pena-Hernandez R, et al., 2021 [163] |
| BAZ2-ICR | BAZ2A |